Introduction {#Sec1}
============

In December 2019, novel coronavirus (SARS-CoV-2) infection (COVID-19) has emerged in China and spread with amazing speed worldwide and resulted in the pandemic \[[@CR1]\]. The pandemic has deep and serious impact not only on the medical service but also on socio-economic activity worldwide. More than 7 million people were infected, and more than 400,000 people were dead in the world at the moment of early June 2020 \[[@CR2]\]. In addition to the absence of specific treatment and effective vaccine, it makes infection control very difficult that there are many infected patients with no symptom and slight illness, who spread virus into the society insidiously.

The Japanese Government pronounced emergency declaration on April 7, and infection eventually burnt down in 2 months. However, the problem in the future infection control for the 2nd wave of COVID-19 is not solved fundamentally yet. In this context, the epidemiological analysis in the society by using the test for antibodies is expected to give important information for the future public health strategy.

According to the concept above, we have investigated anti-SARS-CoV-2 antibody in hospitalized infected patients in our institute by using three different enzyme-linked immunosorbent assay (ELISA) kits.

Patients and Methods {#Sec2}
====================

Twenty six patients who were diagnosed as COVID-19 from positive RT-PCR test for SARS-CoV-2 by using naso-pharynx swab specimens and admitted in our hospital between April 12 and May 8, 2020 were involved in this study. RT-PCR test was performed at SRL laboratory (Tokyo, Japan). All patients had fever at admission and received chest computed tomography (CT) examination to detect pneumonia. The initial day with a temperature of 37.5 °C and more was determined as a first day of the disease. A total of 45 serum samples from 26 COVID-19 patients obtained between the 1st and 29th days of the disease were used for this study. As negative controls, we used serum samples from 12 patients who were admitted during the same period because of pneumonia and confirmed not to be as COVID-19 because of negative RT-PCR test for SARS-CoV-2 and the comprehensive clinical evaluations. This study was approved by the institutional review board as No2010. The written informed consent was waived for emerging infectious disease, and informed consent was secured by opt-out manner.

Statistical analysis was performed by Mann-Whitney *U* test, and *p* \< 0.05 was considered as significant.

ELISA Test for Anti-SARS-CoV-2 IgG and IgM Antibodies {#Sec3}
=====================================================

ELISA tests used in this study were 2019-nCoV Ab Test (INNOVITA Biological Technology Co., China), COVID-19 IgG/IgM Rapid Test Cassette (Zhejiang Orient Gene Biotech Co., China), and 2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou AllTest Biotech Co., China), which were kindly provided by SoftBank Cooperation (Tokyo, Japan) as a donation. Test was performed according to the protocol of each manufacturer. The result was confirmed by at least two inspectors and adopted only in case with unanimous decision.

Results {#Sec4}
=======

The summary of patient's profile is presented in Table [1](#Tab1){ref-type="table"}. All patients had pneumonia at admission, which was confirmed by chest CT examination. Among 26 patients with COVID-19, 7 patients required mechanical ventilator support, which were designated as severe patients and one patient among them died because of multiple organ failure. The other 19 patients were named as moderate cases. As shown in Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}, anti-SARS-CoV-2 IgG and IgM antibodies turned to be partially positive between the 6th and 10th days, more than 84% positive between the 11th and 15th days, and 100% after the 16th day. When comparing three ELISA test kits, sensitivity of the anti-SARS-CoV-2 IgM of 2019-nCoV IgG/IgM Rapid Test Cassette was poorer than the other two kits. On the other hand, sensitivity of anti-SARS-CoV-2 IgG was comparable in three test kits. Data not shown, all of three test kits showed no false positive reaction in 12 negative control samples.Table 1The summary of the patients in this cohortPatients26 (male 14, female 12)Age (years)19\~82 (52.6 ± 16.3)Pneumonia26Ventilator usage7WBC (/μL)2700\~11900 (5946 ± 2279)CRP (mg/dL)0.02\~28.34 (6.63 ± 7.63)Death1Table 2The positive ratio of anti-SARS-CoV-2 IgG and IgM antibodies detected by three different ELISA kits1\~5 days6\~10 days11\~15 days16\~20 days21 days\~IgM  AllTest0/1 (0.00)0/10 (0.00)5/17 (0.25)2/9 (0.22)2/6 (0.33)  Orient Gene3/10 (0.30)18/19 (0.95)9/9 (1.00)6/6 (1.00)  INNOVITA0/1 (0.00)2/10 (0.20)16/19 (0.84)9/9 (1.00)6/6 (1.00)IgG  AllTest0/1 (0.00)2/10 (0.20)15/17 (0.88)9/9 (1.00)6/6 (1.00)  Orient Gene5/10 (0.50)17/18 (0.94)9/9 (1.00)6/6 (1.00)  INNOVITA0/1 (0.00)3/10 (0.30)17/19 (0.89)9/9 (1.00)6/6 (1.00)Fig. 1The trends of anti-SARS-CoV-2 IgG and IgM antibodies detected by three different ELISA kits

Table [3](#Tab3){ref-type="table"} presents the summary of moderate and severe patients. The severe patients were significantly older and had more elevated C-reactive protein at admission than those with moderate cases. On the contrary, qualitative trends of anti-SARS-CoV-2 IgG and IgM antibodies were not different between both groups (Fig. [2](#Fig2){ref-type="fig"}; Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).Table 3The profiles of severe and moderate patientsModerateSevere*P* valuePatient number197Age (years)46.8± 14.568.4± 9.1*p* = 0.002\*WBC (/μL)5416± 17077386± 3233*P* = 0.19CRP (mg/dL)3.00± 3.816.5± 7.2*P* = 0.0004\*Death01Mann-Whitney *U* test\*Statistically significantFig. 2Comparison of the trends of anti-SARS-CoV-2 IgG and IgM antibodies between severe and moderate casesTable 4Comparison of positive ratio between severe and moderate cases detected by 2019-nCoV Ab Test (INNOVITA)1\~5 days6\~10 days11\~15 days16\~20 days21 days\~IgM  Moderate2/7 (0.29)12/15 (0.80)7/7 (1.00)2/2 (1.00)  Severe0/1 (0.00)0/3 (0.00)4/4 (1.00)2/2 (1.00)4/4 (1.00)IgG  Moderate3/7 (0.43)13/15 (0.87)7/7 (1.00)2/2 (1.00)  Severe0/1 (0.00)0/3 (0.00)4/4 (1.00)2/2 (1.00)4/4 (1.00)Table 5Comparison of positive ratio between severe and moderate cases detected by COVID-19 IgG/IgM Rapid Test Cassette (Orient Gene)1\~5 days6\~10 days11\~15 days16\~20 days21 days\~IgM  Moderate2/7 (0.29)14/15 (0.93)7/7 (1.00)2/2 (1.00)  Severe1/3 (0.33)4/4 (1.00)2/2 (1.00)4/4 (1.00)IgG  Moderate3/7 (0.43)13/14 (0.93)7/7 (1.00)2/2 (1.00)  Severe2/3 (0.67)4/4 (1.00)2/2 (1.00)4/4 (1.00)

Discussion {#Sec5}
==========

The definitive diagnosis of COVID-19 is based on the detection of SARS-CoV-2 virus from nasopharynx, saliva, or stool by RT-PCR method. However, the diagnostic sensitivity of RT-PCR has been reported to be 70 to 80%, which seems not sufficient enough to conduct a strict strategy for control of the infection prevalence, whereas the sensitivity of antibody test is reported to be approximately 100%, although it requires 1 to 2 weeks after the initiation of illness that IgM and/or IgG antibody turns positive. In this sense, antibody test is not realistic for the diagnostic tool for the acute phase of infection. However, we have experienced a middle-aged man with characteristic pneumonia for COVID-19, who presented negative RT-PCR test for three times in a row. He showed a positive test for anti-SARS-CoV-2 IgG and IgM antibodies later and diagnosed as having COVID-19. In this way, antibody test might be sometimes useful as an indirect diagnostic tool for the sub-acute infection phase, clinically.

Most powerful utility of antibody test is an epidemiological analysis to conduct a proper and efficient strategy for controlling the pandemic of COVID-19. After the 1st wave of pandemic storm of COVID-19 in Japan, broad and precise epidemiological study by using the antibody test is expected to be done as early as possible.

Although our cohort is relatively small, this study presents valuable information for the COVID-19.

In our study, qualitative trends of anti-SARS-CoV-2 IgG and IgM antibodies were almost as same as previous reports from China and Singapore \[[@CR3]--[@CR6]\]. Interestingly, sensitivity of anti-SARS-CoV-2 IgG and IgM antibodies was 100% after 2 weeks in our cohort.

On the other hand, we have to be careful about the sensitivity of different ELISA kits, because some test kits may have poorer sensitivity like anti-SARS-CoV-2 IgM antibody of 2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou AllTest Biotech Co., China) in our study.

We could not observe the negative conversion of anti-SARS-CoV-2 IgM antibody. It is considered that it requires at least 30 days for the negative conversion of anti-SARS-CoV-2 IgM antibody.

Finally, we compared the trends of anti-SARS-CoV-2 IgG and IgM antibodies between severe and moderate cases and found no significant difference. However, we have to be careful about the interpretation, because antibody examined in this study does not necessarily reflect neutralizing activity, which is essential for the prevention of infection. It is required to investigate the neutralizing activity of antibody as well as the quantitative evaluation of antibody level to demonstrate the precise difference of the immunological responses to SARS-CoV-2 infection between severe and moderate cases.

This article is part of the Topical Collection on *Covid-19*

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors would like to express their deep gratitude to all of the medical staff of Musashino Red Cross Hospital, who dedicated themselves to take care of COVID-19 patients.

The authors declare that they have no conflict of interest.

This study was approved by the institutional review board as No2010.

Informed consent was secured by opt-out method.
